: Results from the CHOPIN Phase 2 trial showed significant survival improvements for liver treatment, which may support broader adoption and inclusion in clinical guidelines. Financial Snapshot & Market Performance Google's Finance Data
: The company currently operates 28 active treatment centers and plans to expand to 40 centers by the end of 2026 .
is currently positioned as a high-growth medical device company, with a consensus "Moderate Buy" or "Strong Buy" rating from Wall Street analysts. The company reached a financial turning point in 2025, recording its first year of net income and record-high revenues. Investment Thesis: Why Buy?